Loading
Lung Neoplasms / Cell Line, Tumor / Carcinoma, Non Small Cell Lung · Journal article
Cancer Biology & Therapy · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic study demonstrating that TXNRD1 regulates TGF-β1 autocrine signaling to promote epithelial-mesenchymal transition and stemness in NSCLC cell lines, and that TXNRD1 inhibition reduces metastatic tumor growth in a mouse orthotopic model. The work identifies a pathway but does not provide clinical evidence of efficacy, safety, or survival benefit in humans.
In vitro mechanistic study with orthotopic mouse model validation. NSCLC cell lines and orthotopic mouse model; stage-progression analysis used TCGA and GEO databases. Intervention: TXNRD1 overexpression or knockdown (CRISPR/Cas9, siRNA); TXNRD1 inhibition with TRi-1 in vivo. Compared with: TXNRD1-WT cells; control (non-manipulated) cells.
TXNRD1 expression was ~2-fold higher in advanced-stage NSCLC versus early stage in TCGA and GEO databases TXNRD1 knockdown (CRISPR/Cas9 or siRNA) reduced EMT-associated genes and decreased TGF-β1 production in A549 and H226 cells TXNRD1 overexpression increased EMT and stemness markers and produced larger, more compact spheres with higher sphere numbers in H1299 cells
Generalizability to human NSCLC unclear; cell lines and xenograft models do not capture human tumor microenvironment or pharmacokinetics
This work provides a mechanistic rationale for investigating TXNRD1 inhibition as a therapeutic target in NSCLC. However, preclinical findings do not yet support clinical translation; human trials would be needed to establish safety, tolerability, and efficacy.
Mechanistic study in cell lines and a mouse model identifying a pathway without clinical endpoint data or direct evidence of therapeutic benefit in humans.
As stated by the source record.
Quoted from the source exactly as published.
This work provides a mechanistic rationale for investigating TXNRD1 inhibition as a therapeutic target in NSCLC. However, preclinical findings do not yet support clinical translation; human trials would be needed to establish safety, tolerability, and efficacy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Cellular plasticity and epithelial-mesenchymal transition (EMT) promote the initiation and progression of non-small cell lung cancer (NSCLC). Thioredoxin reductase 1 (TXNRD1), a key redox enzyme, has been linked to malignancy, but its mechanism in NSCLC remains unclear. We examined whether TXNRD1 regulates TGF-β1 autocrine signaling to drive EMT and stemness. Stage-progression gene profiles were analyzed in the TCGA and GEO databases with an emphasis on redox gene families. TXNRD1 was manipulated by overexpression or knockdown in A549, H226, and H1299 cells, followed by migration/invasion, spheroid assays, ELISA for cytokines, and RT-qPCR/Western blot for EMT markers. RNA-seq with pathway enrichment analyses was used to identify downstream programs. An orthotopic lung cancer mouse model was established using TXNRD1-WT cells, TXNRD1-deficient cells, and TXNRD1-deficient cells treated with TRi-1. Tumor progression was monitored by bioluminescence imaging at 6 and 12 weeks after transplantation. TXNRD1 expression was ~2-fold higher in advanced-stage NSCLC and was validated in tumor tissues. CRISPR/Cas9 or siRNA knockdown reduced EMT-associated genes and decreased TGF-β1 production in A549 and H226 cells. TXNRD1 overexpression increased EMT and stemness markers and produced larger, more compact spheres with higher sphere numbers in H1299 cells. RNA-seq indicated the TXNRD1 pathway activates the TGF-β1 pathway to promote EMT, motility, and stemness via an autocrine loop; knockdown or TXNRD1 inhibition suppressed metastatic tumor growth in vivo. Our study identifies TXNRD1 as a crucial regulator of cellular plasticity and metastasis in NSCLC via the TGF-β1 pathway, suggesting that targeting TXNRD1 may reduce metastatic potential and improve patient survival.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.